Halozyme Therapeutics, Inc. (HALO) Profit Margins
Over the twelve months to 2026-06-30, Halozyme Therapeutics, Inc. (HALO) had gross margin 82.4%, operating margin 35.9%, net margin 24.9%, free cash flow margin 48.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HALOHalozyme Therapeutics, Inc.Follow HALO — free
—
Price chart with a free account
- Market cap
- 14.3B
- P/E TTM
- 36.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 99.5% | 97.4% | 88.6% | 69.8% | 78.3% | 77.4% | 90.2% | 93.3% | 76.8% | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% | 82.4% | |
| Operating margin | -35.4% | -126.7% | -146.8% | -83.7% | -20.3% | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% | 35.9% | |
| Net margin | -35.2% | -126.5% | -152.3% | -90.8% | -23.9% | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% | 24.9% | |
| FCF margin | -62.6% | -155.2% | -94.2% | -64.9% | -29.2% | -36.5% | 41.9% | -35.7% | -45.6% | 19.8% | 67.2% | 35.6% | 45.0% | 46.1% | 46.2% | 48.5% |
USD billions · SEC XBRL
Halozyme Therapeutics, Inc. — questions
- What is Halozyme Therapeutics, Inc.'s gross margin?
- 82.4% over the twelve months to 2026-06-30.
- What is Halozyme Therapeutics, Inc.'s operating margin?
- 35.9% over the twelve months to 2026-06-30.
- What is Halozyme Therapeutics, Inc.'s net profit margin?
- 24.9% over the twelve months to 2026-06-30.
Every figure on this page comes from Halozyme Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.